TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05334823: A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Sponsor: Chongqing Precision Biotech Co., Ltd · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,272,800

Rescue Site Savings

+$7,438,200

Unlock Full NCT05334823 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05334823 Rescue Dossier →